Join us for an engaging panel discussion featuring industry experts and leaders as we explore the transformative effects of the Inflation Reduction Act on drug pricing and pharmaceutical innovation. This conversation will dive into the policy’s implications for affordability, access, and the future of medical breakthroughs, highlight strategies and business models reshaping the healthcare landscape, and provide valuable insights into one of the most pressing topics in healthcare today.

Featured Speakers:

• Kristi Martin, Director of Health Care at Camber Collective, and Former Senior Advisor at Centers for Medicare and Medicaid Services (CMS)
• Shuvayu Sen, Vice President and Head of Oncology, Center of Observational & Real World Evidence at Merck
• Sam Wollner ’14, Vice President, Strategy & Partnerships at EmblemHealth
• (Moderator) Xuelin Li, Assistant Professor of Finance at Columbia Business School